Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This open-label phase II trial studies how well niraparib works in treating patients with
advanced, metastatic melanoma with the homologous recombination (HR) pathway gene mutation /
alteration. Niraparib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. The trial is designed to assess the efficacy and safety of niraparib
in patients with HR mutation/ alteration whose disease progressed on prior immunotherapy
and/or BRAF-targeting therapy.
Phase:
Phase 2
Details
Lead Sponsor:
California Pacific Medical Center Research Institute
Collaborators:
Huntsman Cancer Institute Mt. Sinai Medical Center, Miami Tesaro, Inc. Vanderbilt-Ingram Cancer Center